Michael Untch
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Huober J, Hackman J, Dasappa L, Ciruelos E, Toral Pena J, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber R, Piccart-Gebhart M, Jouannaud C, Wildiers H, Lecocq C, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Láng I, Smith I, Boyle F, Xu B, Di Cosimo S. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer 2019; 118:169-177.
Aug 1, 2019Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Aug 1, 2019Eur J Cancer 2019; 118:169-177
Huober Jens, Hackman John, Dasappa Lokanatha, Ciruelos Eva, Toral Pena Juan Carlos, Adamchuk Hryhoriy, Hickish Tamas, de la Pena Lorena, Jackisch Christian, Gelber Richard D, Piccart-Gebhart Martine, Jouannaud Christelle, Wildiers Hans, Lecocq Christophe, Holmes Eileen, Baselga José, de Azambuja Evandro, Untch Michael, Fumagalli Debora, Sarp Severine, Láng István, Smith Ian, Boyle Frances, Xu Binghe, Di Cosimo Serena
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019
Ditsch N, Schmidt M, Rody A, Rhiem K, Nitz U, Mundhenke C, Müller-Schimpfle M, Möbus V, Maass N, Lux M, Schneeweiss A, Schütz F, Wöckel A, Witzel I, Wenz F, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Luftner D, Loibl S, Kümmel S, Diel I, Dall P, Budach W, Blohmer J, Bauerfeind I, Albert U, Müller V, Janni W, Jackisch C, Fasching P, Fehm T, Kühn T, Krug D, Kreipe H, Kolberg-Liedtke C, Huober J, Harbeck N, Hanf V, Gerber B, Friedrich M, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care (Basel) 2019; 14:247-255.
Jul 30, 2019AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019
Jul 30, 2019Breast Care (Basel) 2019; 14:247-255
Ditsch Nina, Schmidt Marcus, Rody Achim, Rhiem Kerstin, Nitz Ulrike, Mundhenke Christoph, Müller-Schimpfle Markus, Möbus Volker, Maass Nicolai, Lux Michael Patrick, Schneeweiss Andreas, Schütz Florian, Wöckel Achim, Witzel Isabell, Wenz Frederik, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Sinn Hans-Peter, Luftner Diana, Loibl Sibylle, Kümmel Sherko, Diel Ingo, Dall Peter, Budach Wilfried, Blohmer Jens, Bauerfeind Ingo, Albert Ute-Susann, Müller Volkmar, Janni Wolfgang, Jackisch Christian, Fasching Peter A, Fehm Tanja, Kühn Thorsten, Krug David, Kreipe Hans-Heinrich, Kolberg-Liedtke Cornelia, Huober Jens, Harbeck Nadia, Hanf Volker, Gerber Bernd, Friedrich Michael, Thill Marc
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials
Krug D, Huober J, Jackisch C, Kümmel S, Paepke S, Schem C, Schneeweiss A, Untch M, Debus J, von Minckwitz G, Kühn T, Hilfrich J, Heil J, Lederer B, Seither F, Nekljudova V, Ataseven B, Blohmer J, Costa S, Denkert C, Ditsch N, Gerber B, Hanusch C, Loibl S. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. Ann Surg Oncol 2019; 26:3892-3901.
Jul 26, 2019Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials
Jul 26, 2019Ann Surg Oncol 2019; 26:3892-3901
Krug David, Huober Jens, Jackisch Christian, Kümmel Sherko, Paepke Stefan, Schem Christian, Schneeweiss Andreas, Untch Michael, Debus Jürgen, von Minckwitz Gunter, Kühn Thorsten, Hilfrich Jörn, Heil Joerg, Lederer Bianca, Seither Fenja, Nekljudova Valentina, Ataseven Beyhan, Blohmer Jens-Uwe, Costa Serban Dan, Denkert Carsten, Ditsch Nina, Gerber Bernd, Hanusch Claus, Loibl Sibylle
Fatal events during clinical trials: an evaluation of deaths during breast cancer studies
Furlanetto J, Mehta K, Nekljudova V, Untch M, Thomssen C, Hanusch C, Lück H, Nitz U, Bauerfeind I, Gerber B, Fasching P, Huober J, Schneeweiss A, Möbus V, Lederer B, von Minckwitz G, Loibl S. Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. Breast Cancer 2019; 26:826-834.
Jun 28, 2019Fatal events during clinical trials: an evaluation of deaths during breast cancer studies
Jun 28, 2019Breast Cancer 2019; 26:826-834
Furlanetto Jenny, Mehta Keyur, Nekljudova Valentina, Untch Michael, Thomssen Christoph, Hanusch Claus, Lück Hans-Joachim, Nitz Ulrike, Bauerfeind Ingo, Gerber Bernd, Fasching Peter A, Huober Jens, Schneeweiss Andreas, Möbus Volker, Lederer Bianca, von Minckwitz Gunter, Loibl Sibylle
Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019)
Untch M, Kühn T, Luftner D, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thill M, Wuerstlein R, Fasching P, Kolberg-Liedtke C, Kolberg H, Thomssen C, Bauerfeind I, Braun M, Brucker S, Felberbaum R, Hagemann F, Haidinger R, Hönig A, Huober J, Jackisch C, Harbeck N. Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). Geburtshilfe Frauenheilkd 2019; 79:591-604.
Jun 14, 2019Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019)
Jun 14, 2019Geburtshilfe Frauenheilkd 2019; 79:591-604
Untch Michael, Kühn Thorsten, Luftner Diana, Maass Nicolai, Reimer Toralf, Schneeweiss Andreas, Schumacher-Wulf Eva, Schütz Florian, Thill Marc, Wuerstlein Rachel, Fasching Peter A, Kolberg-Liedtke Cornelia, Kolberg Hans-Christian, Thomssen Christoph, Bauerfeind Ingo, Braun Michael, Brucker Sara Y, Felberbaum Ricardo, Hagemann Friederike, Haidinger Renate, Hönig Arnd, Huober Jens, Jackisch Christian, Harbeck Nadia
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
Untch M, Hackmann J, Blohmer J, Rhiem K, Schmitt W, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Hanusch C, Just M, Fasching P, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Loibl S. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J Clin Oncol 2019; 37:2226-2234.
May 13, 2019NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
May 13, 2019J Clin Oncol 2019; 37:2226-2234
Untch Michael, Hackmann John, Blohmer Jens-Uwe, Rhiem Kerstin, Schmitt Wolfgang D, Furlanetto Jenny, Gerber Bernd, Huober Jens, Nekljudova Valentina, von Minckwitz Gunter, Hanusch Claus, Just Marianne, Fasching Peter A, Jackisch Christian, Schneeweiss Andreas, Schmatloch Sabine, Aktas Bahriye, Denkert Carsten, Schem Christian, Wiebringhaus Hermann, Kümmel Sherko, Warm Mathias, Loibl Sibylle
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
Laakmann E, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Blohmer J, Zahm D, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Loibl S. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Res 2019; 21:60.
May 10, 2019Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
May 10, 2019Breast Cancer Res 2019; 21:60
Laakmann Elena, Ingold-Heppner Barbara, Huober Jens, Hanusch Claus, Jackisch Christian, Reinisch Mattea, Untch Michael, von Minckwitz Gunter, Nekljudova Valentina, Müller Volkmar, Blohmer Jens-Uwe, Zahm Dirk-Michael, Witzel Isabell, Fasching Peter A, Rezai Mahdi, Schem Christian, Solbach Christine, Tesch Hans, Klare Peter, Schneeweiss Andreas, Salat Christoph, Loibl Sibylle
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
Lux M, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Schneeweiss A, Belleville E, Beckmann M, Müller V, Nabieva N, Hartkopf A, Huober J, Volz B, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Brucker S. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. Cancers (Basel) 2018; 11
Dec 21, 2018Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
Dec 21, 2018Cancers (Basel) 2018; 11
Lux Michael P, Wimberger Pauline, Hielscher Carsten, Geberth Matthias, Abenhardt Wolfgang, Kurbacher Christian, Wuerstlein Rachel, Thomssen Christoph, Untch Michael, Fasching Peter A, Janni Wolfgang, Fehm Tanja N, Wallwiener Diethelm, Schneeweiss Andreas, Belleville Erik, Beckmann Matthias W, Müller Volkmar, Nabieva Naiba, Hartkopf Andreas D, Huober Jens, Volz Bernhard, Taran Florin-Andrei, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Luftner Diana, Wallwiener Markus, Brucker Sara Y
Management of HER2-Positive Early Breast Cancer
Steger G, Luftner D, Stöger H, Thürlimann B, Untch M. Management of HER2-Positive Early Breast Cancer. Breast Care (Basel) 2018; 13:453-455.
Dec 5, 2018Management of HER2-Positive Early Breast Cancer
Dec 5, 2018Breast Care (Basel) 2018; 13:453-455
Steger Günther, Luftner Diana, Stöger Herbert, Thürlimann Beat, Untch Michael
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
Schneeweiss A, Ingold-Heppner B, Blohmer J, Rezai M, Frank M, Engels K, Rhiem K, Fasching P, Nekljudova V, von Minckwitz G, Thomalla J, Jackisch C, Kast K, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Loibl S. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer 2018; 106:181-192.
Dec 5, 2018Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
Dec 5, 2018Eur J Cancer 2018; 106:181-192
Schneeweiss Andreas, Ingold-Heppner Barbara, Blohmer Jens-Uwe, Rezai Mahdi, Frank Matthias, Engels Knut, Rhiem Kerstin, Fasching Peter Andreas, Nekljudova Valentina, von Minckwitz Gunter, Thomalla Jörg, Jackisch Christian, Kast Karin, Möbus Volker, Tesch Hans, Hanusch Claus, Denkert Carsten, Lübbe Kristina, Huober Jens, Klare Peter, Kümmel Sherko, Untch Michael, Loibl Sibylle
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
Bjelic-Radisic V, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M, Blohmer J, Fasching P, Sinn H, Hirsmüller S, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Lux M, Harbeck N, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Buck A, Nöthlings U, Müller V, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H, von Minckwitz G, Möbus V, Stangl S, Paradies K, Wöckel A, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Kreienberg R, Kopp I, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann P, Jírů-Hillmann S, Albert U, Budach W, Follmann M, Janni W, Steckelberg A, Feyer P, Petersen C, Bartsch H, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Siedentopf F, Lebeau A, König K, Hahne A, Baumgartner T, Kreipe H, Knoefel W, Denkinger M, Brucker S, Luftner D, Kubisch C, Gerlach C, Honegger C. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2018; 78:1056-1088.
Nov 26, 2018Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
Nov 26, 2018Geburtshilfe Frauenheilkd 2018; 78:1056-1088
Bjelic-Radisic Vesna, Dunst Jürgen, Münstedt Karsten, Bick Ulrich, Fallenberg Eva, Tholen Reina, Hung Roswita, Baumann Freerk, Beckmann Matthias W, Blohmer Jens, Fasching Peter, Sinn Hans-Peter, Hirsmüller Susanne, Degenhardt Friedrich, Wenz Frederik, Rick Oliver, Hölzel Dieter, Zaiss Matthias, Kemper Gudrun, Budach Volker, Denkert Carsten, Gerber Bernd, Tesch Hans, Lux Michael P, Harbeck Nadia, Schmidt Marcus, Schmutzler Rita, Schneeweiss Andreas, Schütz Florian, Stickeler Elmar, Thomssen Christoph, Untch Michael, Wesselmann Simone, Bücker Arno, Buck Andreas, Nöthlings Ute, Müller Volkmar, Hadji Peyman, Hauner Hans, Heywang-Köbrunner Sylvia, Huober Jens, Hübner Jutta, Jackisch Christian, Loibl Sibylle, Lück Hans-Jürgen, von Minckwitz Gunter, Möbus Volker, Stangl Stephanie, Paradies Kerstin, Wöckel Achim, Kühn Thorsten, Langer Thomas, Nothacker Monika, Scharl Anton, Schreer Ingrid, Link Hartmut, Engel Jutta, Fehm Tanja, Weis Joachim, Welt Anja, Kreienberg Rolf, Kopp Ina, Festl Jasmin, Stüber Tanja, Brust Katharina, Krockenberger Mathias, Heuschmann Peter U, Jírů-Hillmann Steffi, Albert Ute-Susann, Budach Wilfried, Follmann Markus, Janni Wolfgang, Steckelberg Anke, Feyer Petra, Petersen Cordula, Bartsch Hans Helge, Schulz-Wendtland Rüdiger, Hahn Markus, Hanf Volker, Müller-Schimpfle Markus, Henscher Ulla, Roncarati Renza, Katalinic Alexander, Heitmann Christoph, Siedentopf Friederike, Lebeau Annette, König Klaus, Hahne Andrea, Baumgartner Traudl, Kreipe Hans H, Knoefel Wolfram Trudo, Denkinger Michael, Brucker Sara, Luftner Diana, Kubisch Christian, Gerlach Christina, Honegger Christoph
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer
Bjelic-Radisic V, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M, Blohmer J, Sinn H, Hirsmüller S, Tesch H, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Fasching P, Lux M, Harbeck N, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Nöthlings U, Müller V, Möbus V, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H, von Minckwitz G, Krockenberger M, Wöckel A, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Kühn T, Kreienberg R, Kopp I, Festl J, Stüber T, Brust K, Stangl S, Heuschmann P, Albert U, Budach W, Follmann M, Janni W, Steckelberg A, Feyer P, König K, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Bartsch H, Petersen C, Siedentopf F, Hahne A, Kreipe H, Knoefel W, Denkinger M, Brucker S, Luftner D, Kubisch C, Gerlach C, Lebeau A, Paradies K. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe Frauenheilkd 2018; 78:927-948.
Oct 19, 2018Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer
Oct 19, 2018Geburtshilfe Frauenheilkd 2018; 78:927-948
Bjelic-Radisic Vesna, Dunst Jürgen, Münstedt Karsten, Bick Ulrich, Fallenberg Eva, Tholen Reina, Hung Roswita, Baumann Freerk, Beckmann Matthias W, Blohmer Jens, Sinn Hans-Peter, Hirsmüller Susanne, Tesch Hans, Degenhardt Friedrich, Wenz Frederik, Rick Oliver, Hölzel Dieter, Zaiss Matthias, Kemper Gudrun, Budach Volker, Denkert Carsten, Gerber Bernd, Fasching Peter A, Lux Michael P, Harbeck Nadia, Schmidt Marcus, Schmutzler Rita, Schneeweiss Andreas, Schütz Florian, Stickeler Elmar, Thomssen Christoph, Untch Michael, Wesselmann Simone, Bücker Arno, Nöthlings Ute, Müller Volkmar, Möbus Volker, Hadji Peyman, Hauner Hans, Heywang-Köbrunner Sylvia, Huober Jens, Hübner Jutta, Jackisch Christian, Loibl Sibylle, Lück Hans-Jürgen, von Minckwitz Gunter, Krockenberger Mathias, Wöckel Achim, Langer Thomas, Nothacker Monika, Scharl Anton, Schreer Ingrid, Link Hartmut, Engel Jutta, Fehm Tanja, Weis Joachim, Welt Anja, Kühn Thorsten, Kreienberg Rolf, Kopp Ina, Festl Jasmin, Stüber Tanja, Brust Katharina, Stangl Stephanie, Heuschmann Peter U, Albert Ute-Susann, Budach Wilfried, Follmann Markus, Janni Wolfgang, Steckelberg Anke, Feyer Petra, König Klaus, Schulz-Wendtland Rüdiger, Hahn Markus, Hanf Volker, Müller-Schimpfle Markus, Henscher Ulla, Roncarati Renza, Katalinic Alexander, Heitmann Christoph, Honegger Christoph, Bartsch Hans Helge, Petersen Cordula, Siedentopf Friederike, Hahne Andrea, Kreipe Hans H, Knoefel Wolfram Trudo, Denkinger Michael, Brucker Sara, Luftner Diana, Kubisch Christian, Gerlach Christina, Lebeau Annette, Paradies Kerstin
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
Fasching P, Huober J, Liedtke C, Weinshilboum R, Wang L, Ingle J, Müller V, Nekljudova V, Weber K, Rack B, Rübner M, von Minckwitz G, Fehm T, Blohmer J, Costa S, Loibl S, Hu C, Hart S, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Couch F. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 2018; 36:2281-2287.
May 23, 2018BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
May 23, 2018J Clin Oncol 2018; 36:2281-2287
Fasching Peter A, Huober Jens, Liedtke Cornelia, Weinshilboum Richard M, Wang Liewei, Ingle James N, Müller Volkmar, Nekljudova Valentina, Weber Karsten E, Rack Brigitte, Rübner Matthias, von Minckwitz Gunter, Fehm Tanja, Blohmer Jens-Uwe, Costa Serban Dan, Loibl Sibylle, Hu Chunling, Hart Steven N, Shimelis Hermela, Moore Raymond, Schem Christian, Tesch Hans, Untch Michael, Hilfrich Jörn, Rezai Mahdi, Gerber Bernd, Couch Fergus J
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Untch M, Loibl S, Nekljudova V, Fehm T, Hauschild M, Blohmer J, Kunz G, Jackisch C, Solbach C, Huober J, Hanusch C, Eggemann H, Tesch H, Fasching P, Rezai M, Schem C, Gerber B, von Minckwitz G, GBG and the AGO-B Study Group. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). J Clin Oncol 2018; 36:1308-1316.
Mar 15, 2018Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Mar 15, 2018J Clin Oncol 2018; 36:1308-1316
Untch Michael, Loibl Sibylle, Nekljudova Valentina, Fehm Tanja, Hauschild Maik, Blohmer Jens-Uwe, Kunz Georg, Jackisch Christian, Solbach Christine, Huober Jens, Hanusch Claus, Eggemann Holm, Tesch Hans, Fasching Peter A, Rezai Mahdi, Schem Christian, Gerber Bernd, von Minckwitz Gunter, GBG and the AGO-B Study Group
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Loibl S, Liu X, Symmans W, Rastogi P, Metzger Filho O, Ponce Lorenzo J, McIntyre K, Wolmark N, Sullivan D, Maag D, von Minckwitz G, Golshan M, Huober J, McKee M, Rugo H, Sikov W, Untch M, O'Shaughnessy J, Geyer C. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018; 19:497-509.
Feb 28, 2018Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Feb 28, 2018Lancet Oncol 2018; 19:497-509
Loibl Sibylle, Liu Xuan, Symmans W Fraser, Rastogi Priya, Metzger Filho Otto, Ponce Lorenzo Jose J, McIntyre Kristi, Wolmark Norman, Sullivan Danielle, Maag David, von Minckwitz Gunter, Golshan Mehra, Huober Jens, McKee Mark D, Rugo Hope S, Sikov William M, Untch Michael, O'Shaughnessy Joyce, Geyer Charles E
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Denkert C, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching P, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Kümmel S, Pfitzner B, Karn T, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt W, Blohmer J, Loibl S. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2017; 19:40-50.
Dec 7, 2017Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Dec 7, 2017Lancet Oncol 2017; 19:40-50
Denkert Carsten, Engels Knut, Schneeweiss Andreas, Hartmann Arndt, Noske Aurelia, Fasching Peter A, Jackisch Christian, van Mackelenbergh Marion, Sinn Peter, Schem Christian, Hanusch Claus, Untch Michael, Kümmel Sherko, Pfitzner Berit M, Karn Thomas, von Minckwitz Gunter, Darb-Esfahani Silvia, Lederer Bianca, Heppner Barbara I, Weber Karsten E, Budczies Jan, Huober Jens, Klauschen Frederick, Furlanetto Jenny, Schmitt Wolfgang D, Blohmer Jens-Uwe, Loibl Sibylle
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
Hartkopf A, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Brucker S, Belleville E, Beckmann M, Müller V, Huober J, Volz B, Nabieva N, Taran F, Schwitulla J, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lux M, Luftner D, Wallwiener M, Schneeweiss A. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. Breast 2017; 37:42-51.
Oct 26, 2017Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
Oct 26, 2017Breast 2017; 37:42-51
Hartkopf Andreas D, Wimberger Pauline, Hielscher Carsten, Geberth Matthias, Fersis Nikos, Abenhardt Wolfgang, Kurbacher Christian, Wuerstlein Rachel, Thomssen Christoph, Untch Michael, Fasching Peter A, Janni Wolfgang, Fehm Tanja N, Wallwiener Diethelm, Brucker Sara Y, Belleville Erik, Beckmann Matthias W, Müller Volkmar, Huober Jens, Volz Bernhard, Nabieva Naiba, Taran Florin-Andrei, Schwitulla Judith, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Lux Michael P, Luftner Diana, Wallwiener Markus, Schneeweiss Andreas
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial
Hahnen E, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Neidhardt G, Schem C, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching P, Blohmer J, Jackisch C, Paepke S, Gerber B, Kümmel S, Schmutzler R. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol 2017; 3:1378-1385.
Oct 1, 2017Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial
Oct 1, 2017JAMA Oncol 2017; 3:1378-1385
Hahnen Eric, Huober Jens, Rhiem Kerstin, Costa Serban, Altmüller Janine, Hanusch Claus, Thiele Holger, Müller Volkmar, Nürnberg Peter, Karn Thomas, Nekljudova Valentina, Untch Michael, von Minckwitz Gunter, Neidhardt Guido, Schem Christian, Lederer Bianca, Hauke Jan, Loibl Sibylle, Kröber Sandra, Schneeweiss Andreas, Denkert Carsten, Fasching Peter A, Blohmer Jens U, Jackisch Christian, Paepke Stefan, Gerber Bernd, Kümmel Sherko, Schmutzler Rita K
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials
van Mackelenbergh M, Weber K, von Minckwitz G, Untch M, Schneeweiss A, Müller V, Kümmel S, Blohmer J, Fasching P, Huober J, Hanusch C, Jackisch C, Stickeler E, Marme F, Schem C, Karn T, Nekljudova V, Denkert C, Loibl S. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat 2017; 167:59-71.
Sep 5, 2017Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials
Sep 5, 2017Breast Cancer Res Treat 2017; 167:59-71
van Mackelenbergh Marion T, Weber Karsten E, von Minckwitz Gunter, Untch Michael, Schneeweiss Andreas, Müller Volkmar, Kümmel Sherko, Blohmer Jens-Uwe, Fasching Peter A, Huober Jens, Hanusch Claus, Jackisch Christian, Stickeler Elmar, Marme Frederik, Schem Christian, Karn Thomas, Nekljudova Valentina, Denkert Carsten, Loibl Sibylle
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Kümmel S, Burchardi N, von Minckwitz G, Fasching P, Klare P, Engels K, Denkert C, Schneeweiss A, Jackisch C, Hilfrich J, Hanusch C, Gerber B, Eiermann W, Blohmer J, Untch M, Schem C, Huober J, Paepke S, Loibl S. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Eur J Cancer 2017; 84:1-8.
Jul 30, 2017Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Jul 30, 2017Eur J Cancer 2017; 84:1-8
Kümmel Sherko, Burchardi Nicole, von Minckwitz Gunter, Fasching Peter A, Klare Peter, Engels Knut, Denkert Carsten, Schneeweiss Andreas, Jackisch Christian, Hilfrich Jörn, Hanusch Claus, Gerber Bernd, Eiermann Wolfgang, Blohmer Jens Uwe, Untch Michael, Schem Christian, Huober Jens, Paepke Stefan, Loibl Sibylle